Inside NEU: The ASX pharma star with a long runway for growth
Host Mitchell Sneddon interviews Jon Pilcher, CEO of Neuren Pharmaceuticals, about the company's growth following the FDA approval of Trofenetide for Rett Syndrome. The discussion covers drug development, the company's self-funded pipeline, and the potential of NNZ-2591.